Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study

Open access
Fernández, Oscar, Izquierdo, Guillermo, Fernández, Victoria, Leyva, Laura, Reyes, Virginia, Guerrero, Miguel, León, Antonio, Arnaiz, Carlos, Navarro, Guillermo, Páramo, Maria Dolores, Cuesta, Antonio De la, Soria, Bernat, Hmadcha, Abdelkrim, Pozo, David, Fernandez-Montesinos, Rafael, Leal, Maria, Ochotorena, Itziar, Gálvez, Patricia, Geniz, Maria Angeles, Barón, Francisco Javier, Mata, Rosario, Medina, Cristina, Caparrós-Escudero, Carlos, Cardesa, Ana, Cuende, Natividad, on behalf of the Research Group Study EudraCT 2008-004015-35 · 2018 · PLOS ONE

Abstract

BACKGROUND: Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using minimally invasive procedures. PATIENTS AND METHODS: In this triple-blind, placebo-controlled study, cell samples were obtained from consenting patients by lipectomy and subsequently expanded. Patients were randomized to a single infusion of placebo, low-dose(1x106cells/kg) or high-dose(4x106cells/kg) autologous AdMSC product and followed for 12 months. Safety was monitored recording adverse events, laboratory parameters, vital signs and spirometry. Expanded disability status score (EDSS), magnetic-resonance-imaging, and other measures of possible treatment effects were also recorded. RESULTS: Thirty-four patients underwent lipectomy for AdMSCs collection, were randomized and thirty were infused (11 placebo, 10 low-dose and 9 high-dose); 4 randomized patients were not infused because of karyotype abnormalities in the cell product. Only one serious adverse event was observed in the treatment arms (urinary infection, considered not related to study treatment). No other safety parameters showed changes. Measures of treatment effect showed an inconclusive trend of efficacy. CONCLUSION: Infusion of autologous AdMSCs is safe and feasible in patients with SPMS. Larger studies and probably treatment at earlier phases would be needed to investigate the potential therapeutic benefit of this technique.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0195891

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 161

Metadata

Authors
Fernández, O., Izquierdo, G., Fernández, V., Leyva, L., Reyes, V., Guerrero, M., León, A., Arnaiz, C., Navarro, G., Páramo, M. D., Cuesta, A. D. L., Soria, B., Hmadcha, A., Pozo, D., Fernandez-Montesinos, R., Leal, M., Ochotorena, I., Gálvez, P., Geniz, M. A., Barón, F. J., Mata, R., Medina, C., Caparrós-Escudero, C., Cardesa, A., Cuende, N., & on behalf of the Research Group Study EudraCT 2008-004015-35
Venue
PLOS ONE
Published
2018-05-16
Volume
13
Issue
5
Pages
e0195891
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2804567596
Cited by
161
References
3
FWCI
11.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. https://app.cochat.ai/papers/10.1371/journal.pone.0195891
The paper
Fernández, O., Izquierdo, G., Fernández, V., Leyva, L., Reyes, V., Guerrero, M., León, A., Arnaiz, C., Navarro, G., Páramo, M. D., Cuesta, A. D. L., Soria, B., Hmadcha, A., Pozo, D., Fernandez-Montesinos, R., Leal, M., Ochotorena, I., Gálvez, P., Geniz, M. A., . . . on behalf of the Research Group Study EudraCT 2008-004015-35. (2018). Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLOS ONE. https://doi.org/10.1371/journal.pone.0195891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.